Page 44 - 2018_12-Haematologica-web

E. Campo et al.
110. Oscier D, Wade R, Davis Z, et al. Prognostic
factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010;95(10): 1705-1712.
111. Hu L, Ru K, Zhang L, et al. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark Res. 2014;2(1):3.
112. Wiktor AE, Van Dyke DL, Stupca PJ, et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med. 2006;8(1):16-23.
113.Zent CS, Burack WR. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53. ASH Education Program Book. 2014;2014(1):119-124.
114. Kelley T, Xu X. The future is now for the laboratory evaluation of myelodysplastic syndromes. The Hematologist. 2014;11(5).
115. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic profiling of chron- ic lymphocytic leukemia reveals new recur- rent genomic alterations. Blood. 2012;120 (24):4783-4794.
116. Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocyt- ic leukemia. Haematologica. 2011;96(8): 1161-1169.
117. Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profil- ing in chronic lymphocytic leukemia: devel- opment of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA. 2004;101(4):1039-1044.
118. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lympho- cytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-con-
trolled trial. Lancet Oncol. 2017;18(3):297-
311.
119.Stilgenbauer S, Eichhorst B, Schetelig J, et
al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19): 1973-1980.
120.Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refrac- tory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120.
121. Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37(9): 865-876.
122. Dufour A, Palermo G, Zellmeier E, et al. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood. 2013;121(18): 3650-3657.
1968
haematologica | 2018; 103(12)